Summary
Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers. In preclinical trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors. Given the promising preclinical outcome and favorable pharmacologic properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC). The primary objective of the study was to determine the 6-month progression-free survival (PFS) rate. Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria. All patients received ganetespib at 200 mg/m2 on days 1, 8, and 15 of every 28 days (one cycle). Subjects who tolerated therapy were continued on ganetespib until disease progression. Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-associated molecular markers were evaluated. Results Eighteen patients were recruited into the trial; most were Caucasian, had performance status 1, had received prior docetaxel, and were heavily pretreated. Of the 17 patients who were treated, none attained 6-month PFS. Only 2 patients achieved PFS > 4 months. The median PFS was 1.9 months. As per the study design, the trial was terminated after the interim analysis. The most frequent types of Grade 3 toxicity were dehydration, diarrhea, and fatigue. Molecular markers provided little additional insight regarding drug activity. Conclusions Ganetespib demonstrated minimal clinical activity in men with mCRPC. The true 6-month PFS rate was, at most, 0.20. Possible reasons for this include selection of a heavily pretreated patient population and lack of agent potency in patients with mCRPC.
Similar content being viewed by others
References
Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):1687–1697
Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD (2004) Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11(3):459–476
Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol Off J Am Soc Clin Oncol 23(32):8253–8261. doi:10.1200/jco.2005.03.4777
Smith DF, Toft DO (2008) Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol (Baltimore, Md) 22(10):2229–2240. doi:10.1210/me.2008-0089
Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537–549. doi:10.1038/nrc2887
Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761–772. doi:10.1038/nrc1716
Cardillo MR, Ippoliti F (2006) IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 26(5a):3409–3416
Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC, Bevan CL (2012) Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol Endocrinol (Baltimore, Md) 26(10):1694–1706. doi:10.1210/me.2012-1056
Weinstein IB (2002) Cancer. Addiction to oncogenes–the achilles heal of cancer. Science (New York, NY) 297(5578):63–64. doi:10.1126/science.1073096
Caplan AJ (1999) Hsp90’s secrets unfold: new insights from structural and functional studies. Trends Cell Biol 9(7):262–268
Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8(5):986–993
Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA (2011) Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 11:468. doi:10.1186/1471-2407-11-468
Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A (2011) A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 17(8):2301–2313. doi:10.1158/1078-0432.ccr-10-3077
O’Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL, Wang Z (2012) Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate 72(10):1117–1123. doi:10.1002/pros.22458
Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14(23):7940–7946. doi:10.1158/1078-0432.ccr-08-0221
Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78(3):626–630. doi:10.1016/j.urology.2011.04.041
Wang Y, Trepel JB, Neckers LM, Giaccone G (2010) STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (London, England : 2000) 11(12):1466–1476
Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11(2):475–484. doi:10.1158/1535-7163.mct-11-0755
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 18(18):4973–4985. doi:10.1158/1078-0432.ccr-11-2967
Cho DC HE, Cleary JM, Kwak EL, Gandhi L, Lawrence DP, Zack C, Teofilovici F, Bradley R, Karol MD, Shapiro G, LoRusso P A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. AM SOC CLIN ONCOL ANN MEET 2011 29 June 3–7 Abs 3051
Goldman JW RR, Gordon GA, Vukovic VM, Bradley R, Rosen LS A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. AM SOC CLIN ONCOL ANN MEET 2010 46 June 5 Abs 2529
Li X, Yin S, Meng Y, Sakr W, Sheng S (2006) Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res 66(18):9323–9329. doi:10.1158/0008-5472.can-06-1578
Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S (2002) Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 21(26):4089–4098. doi:10.1038/sj.onc.1205507
Li X, Chen D, Yin S, Meng Y, Yang H, Landis-Piwowar KR, Li Y, Sarkar FH, Reddy GP, Dou QP, Sheng S (2007) Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J Cell Physiol 212(2):298–306. doi:10.1002/jcp.21102
Tahmatzopoulos A, Sheng S, Kyprianou N (2005) Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene 24(34):5375–5383. doi:10.1038/sj.onc.1208684
Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S (2011) Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes & Cancer 2(11):1009–1022. doi:10.1177/1947601912440170
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10
Hintze J (2008) Power and sample size (PASS). NCSS, Kaysville
Lee E, Wang JW (2003) Statistical methods for survival data analysis 3edn. Wiley, New York
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Tilley WD, Butler LM (2012) Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 18(13):3562–3570. doi:10.1158/1078-0432.ccr-12-0782
Blacklock K, Verkhivker GM (2013) Experimentally guided structural modeling and dynamics analysis of Hsp90-p53 interactions: allosteric regulation of the Hsp90 chaperone by a client protein. J Chem Inf Model 53(11):2962–2978. doi:10.1021/ci400434g
Acknowledgments
This study was partially supported by NIH Cancer Center Support Grant CA022453 (to Bepler, G), NIH grants (CA127735 and CA084176 to Sheng, S), Fund for Cancer Research (to Sheng, S and Heath, E), and the Ruth Sager Memorial Fund (to Sheng, S).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
STA-9090 ([5-[2,4-Dihydroxy-5- (1-methylethyl)phenyl]-4-(1-methyl-1 H-indol-5-yl)-2,4-dihydro-[1, 2, 4]triazol-3-one])
Rights and permissions
About this article
Cite this article
Thakur, M.K., Heilbrun, L.K., Sheng, S. et al. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs 34, 112–118 (2016). https://doi.org/10.1007/s10637-015-0307-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-015-0307-6